Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival

BACKGROUND: Bortezomib offers a novel approach to the treatment of multiple myeloma producing rapid control. The aim of this study was to investigate the outcomes of bortezomib and dexamethasone-treated patients with multiple myeloma. METHODS: We conducted a retrospective study of 44 consecutively-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiba, Takayoshi, Ito, Takuo, Nakashima, Toshihisa, Okikawa, Yoshiko, Kido, Miki, Kimura, Akiko, Kameda, Keita, Miyamae, Fumiaki, Tanaka, Suzuko, Atsumi, Misao, Sumitani, Yoko, Shitakubo, Yoshimi, Niimi, Hiromasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078016/
https://www.ncbi.nlm.nih.gov/pubmed/24952705
http://dx.doi.org/10.1186/1471-2407-14-462
_version_ 1782323680601178112
author Kiba, Takayoshi
Ito, Takuo
Nakashima, Toshihisa
Okikawa, Yoshiko
Kido, Miki
Kimura, Akiko
Kameda, Keita
Miyamae, Fumiaki
Tanaka, Suzuko
Atsumi, Misao
Sumitani, Yoko
Shitakubo, Yoshimi
Niimi, Hiromasa
author_facet Kiba, Takayoshi
Ito, Takuo
Nakashima, Toshihisa
Okikawa, Yoshiko
Kido, Miki
Kimura, Akiko
Kameda, Keita
Miyamae, Fumiaki
Tanaka, Suzuko
Atsumi, Misao
Sumitani, Yoko
Shitakubo, Yoshimi
Niimi, Hiromasa
author_sort Kiba, Takayoshi
collection PubMed
description BACKGROUND: Bortezomib offers a novel approach to the treatment of multiple myeloma producing rapid control. The aim of this study was to investigate the outcomes of bortezomib and dexamethasone-treated patients with multiple myeloma. METHODS: We conducted a retrospective study of 44 consecutively-treated multiple myeloma patients with bortezomib (1.3 mg/m(2) on days 1, 4, 8, and 11 of a 21-day cycle or 1.3 mg/m(2) intravenously 1, 8, 15, and 22 of every 35-day cycle) and dexamethasone. RESULTS: The median time to progression, progression free survival time, and overall survival time in the treatment groups was 14.9, 14.9, and 38.3 months, respectively. The present study also suggests the possibility that the prognosis of patients with high levels of AST and LDH might be worse. CONCLUSIONS: Our results indicate that the treatment of multiple myeloma with bortezomib and dexamethasone is feasible.
format Online
Article
Text
id pubmed-4078016
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40780162014-07-03 Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival Kiba, Takayoshi Ito, Takuo Nakashima, Toshihisa Okikawa, Yoshiko Kido, Miki Kimura, Akiko Kameda, Keita Miyamae, Fumiaki Tanaka, Suzuko Atsumi, Misao Sumitani, Yoko Shitakubo, Yoshimi Niimi, Hiromasa BMC Cancer Research Article BACKGROUND: Bortezomib offers a novel approach to the treatment of multiple myeloma producing rapid control. The aim of this study was to investigate the outcomes of bortezomib and dexamethasone-treated patients with multiple myeloma. METHODS: We conducted a retrospective study of 44 consecutively-treated multiple myeloma patients with bortezomib (1.3 mg/m(2) on days 1, 4, 8, and 11 of a 21-day cycle or 1.3 mg/m(2) intravenously 1, 8, 15, and 22 of every 35-day cycle) and dexamethasone. RESULTS: The median time to progression, progression free survival time, and overall survival time in the treatment groups was 14.9, 14.9, and 38.3 months, respectively. The present study also suggests the possibility that the prognosis of patients with high levels of AST and LDH might be worse. CONCLUSIONS: Our results indicate that the treatment of multiple myeloma with bortezomib and dexamethasone is feasible. BioMed Central 2014-06-21 /pmc/articles/PMC4078016/ /pubmed/24952705 http://dx.doi.org/10.1186/1471-2407-14-462 Text en Copyright © 2014 Kiba et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kiba, Takayoshi
Ito, Takuo
Nakashima, Toshihisa
Okikawa, Yoshiko
Kido, Miki
Kimura, Akiko
Kameda, Keita
Miyamae, Fumiaki
Tanaka, Suzuko
Atsumi, Misao
Sumitani, Yoko
Shitakubo, Yoshimi
Niimi, Hiromasa
Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival
title Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival
title_full Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival
title_fullStr Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival
title_full_unstemmed Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival
title_short Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival
title_sort bortezomib and dexamethasone for multiple myeloma: higher ast and ldh levels associated with a worse prognosis on overall survival
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078016/
https://www.ncbi.nlm.nih.gov/pubmed/24952705
http://dx.doi.org/10.1186/1471-2407-14-462
work_keys_str_mv AT kibatakayoshi bortezomibanddexamethasoneformultiplemyelomahigherastandldhlevelsassociatedwithaworseprognosisonoverallsurvival
AT itotakuo bortezomibanddexamethasoneformultiplemyelomahigherastandldhlevelsassociatedwithaworseprognosisonoverallsurvival
AT nakashimatoshihisa bortezomibanddexamethasoneformultiplemyelomahigherastandldhlevelsassociatedwithaworseprognosisonoverallsurvival
AT okikawayoshiko bortezomibanddexamethasoneformultiplemyelomahigherastandldhlevelsassociatedwithaworseprognosisonoverallsurvival
AT kidomiki bortezomibanddexamethasoneformultiplemyelomahigherastandldhlevelsassociatedwithaworseprognosisonoverallsurvival
AT kimuraakiko bortezomibanddexamethasoneformultiplemyelomahigherastandldhlevelsassociatedwithaworseprognosisonoverallsurvival
AT kamedakeita bortezomibanddexamethasoneformultiplemyelomahigherastandldhlevelsassociatedwithaworseprognosisonoverallsurvival
AT miyamaefumiaki bortezomibanddexamethasoneformultiplemyelomahigherastandldhlevelsassociatedwithaworseprognosisonoverallsurvival
AT tanakasuzuko bortezomibanddexamethasoneformultiplemyelomahigherastandldhlevelsassociatedwithaworseprognosisonoverallsurvival
AT atsumimisao bortezomibanddexamethasoneformultiplemyelomahigherastandldhlevelsassociatedwithaworseprognosisonoverallsurvival
AT sumitaniyoko bortezomibanddexamethasoneformultiplemyelomahigherastandldhlevelsassociatedwithaworseprognosisonoverallsurvival
AT shitakuboyoshimi bortezomibanddexamethasoneformultiplemyelomahigherastandldhlevelsassociatedwithaworseprognosisonoverallsurvival
AT niimihiromasa bortezomibanddexamethasoneformultiplemyelomahigherastandldhlevelsassociatedwithaworseprognosisonoverallsurvival

Ejemplares similares